Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03948763
Title A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

colon adenocarcinoma

pancreatic adenocarcinoma

rectum adenocarcinoma

Advanced Solid Tumor

lung non-small cell carcinoma

Therapies

mRNA 5671

mRNA 5671 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.